BioCentury
DATA GRAPHICS | Data Byte

Assessing market performance after a preclinical IPO

Criticism of the preclinical IPO class not borne out by the numbers

October 26, 2022 12:10 AM UTC

Preclinical IPOs are often criticized for their high-risk nature, but so far, the share prices of preclinical companies that went public in 2017-20 have performed as well as their peers with clinical or marketed assets.

The distribution and median change in share price was similar during the four-year period across the two groups, with the bulk in both cases under water from their IPO price...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article